The high-resolution three-dimensional magnetic detector system 3D-MAGMA accurately measures gastric and small bowel motility in people with type 2 diabetes with neuropathy

Submission date 10/08/2017	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 15/08/2017	Overall study status Completed	 [] Statistical analysis plan [X] Results
Last Edited 01/07/2020	Condition category Nutritional, Metabolic, Endocrine	Individual participant data

Plain English summary of protocol

Background and study aims

Gastroparesis is a motility disorder where the stomach can't empty itself in the normal way and food passes through the stomach more slowly than usual. It is an important complication of diabetes. Motility disorders are underdiagnosed and can lead to unexplained hypoglycemia (low blood sugar). Currently, diagnostic options are limited, and all established methods have disadvantages. The 3D-MAGMA system is capable of reliably measuring stomach and small intestine motility. The aim of this study is to find out whether 3D-MAGMA is able to detect changes in intestinal motility in people with type 2 diabetes and healthy volunteers.

Who can participate?

Patients with type 2 diabetes and healthy volunteers, aged 18-85

What does the study involve?

The participants are positioned in a chair with the 3D-MAGMA-unit attached to it. A magnet is orally administered with 70 ml of water after the recording is started. The time taken for the magnet to pass through the stomach and small intestine is recorded. If the marker stays in the stomach, the measurement is stopped after a minimum of three hours.

What are the possible benefits and risks of participating?

A possible benefit to the participants would be the detection of a gastroparesis which requires medical treatment. 3D-MAGMA is a low risk measuring system. The magnet itself is coated by an inert synthetic material and does not interact with its surroundings. As the marker is magnetic it has to be excreted before having an MRI examination.

Where is the study run from? Friedrich-Schiller-Universität (Germany) When is the study starting and how long is it expected to run for? May 2011 to January 2019

Who is funding the study? University Hospital Jena (Germany)

Who is the main contact? Mr Veit Yves Pascal Jacob

Contact information

Type(s) Scientific

Contact name Mr Veit Yves Pascal Jacob

ORCID ID http://orcid.org/0000-0001-9216-3226

Contact details

Klinik für Innere Medizin IV Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum Jena, Friedrich Schiller Universität Jena Am Klinikum 1 Jena Germany 07747

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers 1.1

Study information

Scientific Title

Measuring people with type 2 diabetes using the high-resolution three-dimensional magnetic detector system 3D-MAGMA - compared to young healthy volunteers to detect changes in gastic and small bowl motility

Study objectives

The aim of the current trial is to determine if 3D-MAGMA is able to detect changes in gastric and small bowel motility in patients with type 2 diabetes compared to healthy controls.

Ethics approval required Old ethics approval format

Ethics approval(s) Local ethics board of Friedrich-Schiller-University Jena, 12/08/2011, ref: 3179- 07/11

Study design Single-centre two-arm open trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

People with type 2 diabetes using insulin and peripheral neuropathy

Interventions

The intervention was an incorporated magnetic capsule detected with the high-resolution threedimensional magnetic detector system 3D-MAGMA. This system is able to track the position and movement of the marker with high accuracy.

Each person was measured once. The measurement took place in the former outpatients department of the KIM III (Department of Internal Medicine III, Endocrinology and Metabolic Diseases University Hospital Jena). The procedure was started between 8:00am and 9:30 am, after fasting for a minimum of 8 hours. Height, weight, blood glucose level, HbA1c, blood pressure and heart rate were all measured prior to the procedure by a study nurse, and a relevant symptomatic history was obtained with a standardized interview (nausea, vomiting, sustained bloating and abdominal and epigastric pain). The whole procedure was supervised by a postgraduate student.

More detailed information regarding the 3D-MAGMA is available at: https://www.ncbi.nlm.nih. gov/pubmed/19095766

Intervention Type Device

Primary outcome measure

Residence time (min) of the capsule in the stomach measured by 3D-MAGMA

Secondary outcome measures

1. Residence time (min) of the capsule in the duodenum measured by 3D-MAGMA

2. Residence time (min) of the capsule in the first 50 cm of the jejunum measured by 3D-MAGMA

Overall study start date

12/05/2011

Completion date

01/01/2019

Eligibility

Key inclusion criteria

Age 18-85 years
 NSS >4/10 and NDS >6/10
 Blood glucose 4-12 mmol/l before testing

4. Written informed consent

Participant type(s) Patient

Age group Adult

Lower age limit 18 Years

Upper age limit 85 Years

Sex Both

Target number of participants 20

Total final enrolment

37

Key exclusion criteria

1. Surgery of stomach or small bowel

2. Opioids, erythromycin, prokinetic agents, L-dopa, ß-agonists, benzodiazepines, ondansetron, tricyclic antidepressives, atropine

3. Eating disorder, portal hypertension, gastric cancer, systemic sclerosis, myotonic dystrophy

4. Pregnancy

5. Implanted cardiac pacemaker/defibrillator

Date of first enrolment 12/03/2013

Date of final enrolment 02/07/2014

Locations

Countries of recruitment Germany

Study participating centre Friedrich-Schiller-Universität Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases) Am Klinikum 1 Jena Germany 07747

Sponsor information

Organisation University Hospital Jena

Sponsor details Klinik für Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie) Universitätsklinikum Jena, Friedrich Schiller Universität Jena Am Klinikum 1 Jena Germany 07747 +49 (0)3641 9324221 Gastro@med.uni-jena.de

Sponsor type Hospital/treatment centre

Website http://www.kim4.uniklinikum-jena.de

ROR https://ror.org/035rzkx15

Funder(s)

Funder type Hospital/treatment centre

Funder Name Universitätsklinikum Jena

Alternative Name(s) Jena University Hospital, UKJ

Funding Body Type Private sector organisation

Funding Body Subtype Universities (academic only)

Location Germany

Results and Publications

Publication and dissemination plan

Additional documents such as study protocol and statistical analysis plan are available upon request. Planned publication in a high-impact peer reviewed journal within the next 12 months.

Intention to publish date

15/02/2021

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Mr Veit Yves Pascal Jacob.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2020	01/07/2020	Yes	No